Cell Biosciences Announces the Appointment of Blaine Bowman as Lead Director

Back to News

Palo Alto, CA (March 31, 2006) — Cell BioSciences Inc. today announced that A. Blaine Bowman has joined its Board as Lead Director. “Mr. Bowman brings an unusual combination of strategic thinking and operating experience in analytical instrumentation,” said Linda Cahill, CEO. “The investment group and management team at Cell BioSciences look forward to having an executive of this caliber helping to guide us as we begin the commercialization of our first product in 2006.”

Blaine Bowman was most recently the President and Chief Executive Officer of Dionex Corporation (NASDAQ: DNEX), a leading developer and manufacturer of laboratory and process analytical systems and related products. Mr. Bowman joined the company in 1977. Under his leadership, Dionex grew from $1 million in sales to over $180 million and is widely respected for its innovative products and solid growth. Earlier, he was a management consultant with McKinsey and Company and a product engineer at Motorola Semiconductor Products Division. Mr. Bowman holds a B.S. Degree in Physics from Brigham Young University and an MBA from Stanford University Graduate School of Business.


Cell BioSciences is a provider of life science analytical instrumentation for protein measurement and identification. The company’s first commercial product, the Firefly™ 3000 will be introduced at the annual meeting of the American Association for Cancer Research April 2 to April 5, 2006. The Firefly system is a nano-fluidics platform that automates and streamlines the tedious technique of Western blotting. Cell BioSciences is located in Palo Alto, CA and can be reached by phone (650 859 1485); on its website (www.cellbiosciences.com) or by email (sales@cellbiosciences.com).


Statements included in this press release that are not historical in nature may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such forward-looking statements include, without limitation, statements regarding any new instruments or tools, any benefits for customers to be derived from new instruments or tools, and the ability of Cell Bioscience’s products to enhance research or achieve market acceptance. Any such forward-looking statements involve risks and uncertainties and reflect Cell Bioscience’s judgment as of the date of this release. The company claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.